To further confirm this observation in a better-controlled immunotherapy cohort, we analyzed ipilimumab (anti-CTLA4 immune checkpoint inhibitor)-treated melanoma patient cohort from Van Allen et al.25 (n = 42 patients). This evidence concerns the gene CTLA4 and melanoma.